Clinical Trial Update: Karenitecin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer [Phase 2]

View source ↗

Summary

The document reports the completion of a Phase 2 clinical trial evaluating Karenitecin for persistent or recurrent ovarian epithelial cancer and primary periton…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Karenitecin

Snippet

Sponsor: Gynecologic Oncology Group | Conditions: Primary Peritoneal Carcinoma, Recurrent Ovarian Carcinoma | Phase 2 | Status: COMPLETED